Immune system activation is essential to thwart the invasion of pathogens and respond appropriately to tissue damage. However, uncontrolled inflammation can result in extensive collateral damage underlying a diverse range of auto-inflammatory, hyper-inflammatory, and neoplastic diseases. The NF-B signaling pathway lies at the heart of the immune system and functions as a master regulator of gene transcription. Thus, this signaling cascade is heavily targeted by mechanisms designed to attenuate overzealous inflammation and promote resolution. Mechanisms associated with the negative regulation of NF-B signaling are currently under intense investigation and have yet to be fully elucidated. Here, we provide an overview of mechanisms that negatively regulate NF-B signaling through either attenuation of signal transduction, inhibition of posttranscriptional signaling, or interference with posttranslational modifications of key pathway components.
INTRODUCTION
Inflammation can be described as a "double-edged sword." On one side, inflammation is a robust and essential biological process that is necessary to protect the host from immediate threats and initiate Abbreviations: ALR, AIM2-like receptor; ARD, ankyrin repeat domain; ARE, AU-rich element; BAFFR, B-cell activating factor receptor; BMDM, bone marrow derived macrophage; cIAP, cellular inhibitors of apoptosis; DD, death domain; DUB, deubiquitinating enzyme; IKK, inhibitor of B kinase; IRAK, interleukin receptor associated kinase; I B, inhibitor of -B;
LT R, lymphotoxin receptor; MALT1, mucosa-associated-lymphoid-tissue lymphoma-translocation gene 1; MEF, mouse embryonic fibroblast; NIK, NF-B inducing kinase; NLR, nod-like receptor; NLS, nuclear localization sequence; PAMP, pathogen-associated molecular pattern; PDCD4, programmed cell death-4; PRR, pattern recognition receptor; RIP1, receptor interaction protein 1; TAK1, TGF-activated kinase-1; TIR, toll/interleukin receptor; TRAF, TNF-receptor-associated factor; TTP, Tristetraprolin; Ub, ubiquitin long-term protective immunity. Conversely, dysregulated inflammation creates highly chaotic conditions in the host and results in excessive tissue damage that ultimately underlies the pathobiology of inflammatory and autoimmune diseases. To date, a large number of studies have focused on deciphering the mechanisms associated with the initiation and propagation of inflammation and inflammatory signaling cascades. Following the initiation and propagation of inflammatory signaling cascades, dynamic mechanisms further ensue that have evolved to reign in overzealous immune responses, promote the resolution of inflammation, and ensure a return to immune system homeostasis once threats to the host have been eliminated.
Pattern recognition receptor (PRR) signaling is a critical component of immune system activation and is typically targeted by mechanisms designed to shut down inflammation and promote resolution.
Broadly, PRRs are located within the cell cytosol, embedded in the cell membrane, or secreted extracellularly. Soluble extracellular PRRs include members of the complement system and the pentraxins that bind to phosphocholine in both a calcium-dependent and -independent manners. 1,2 Membrane-associated receptors include the TLR and Ctype lectin receptor families, whereas cytosolic receptors include the nod-like receptor (NLR), Rig-I-like helicase, and AIM2-like receptor (ALR) families (Fig. 1) . Recognition of a pathogen-associated molecular pattern (PAMP) or damage-associated molecular pattern by a particular PRR leads to rapid pleotropic cellular responses. These cellular responses are driven by a variety of interconnected, coordinated, and complex biochemical signaling pathways, including those driven by the NF-B and IRF transcription factors. The broad and robust biological effects of these pathways both initiate and sustain inflammation and are essential components of the balanced host immune response. This includes the release of proinflammatory cytokines and chemokines that facilitate either cell death or proliferation, the transcription of regulatory elements that silyence target genes regulating hematopoiesis and lymphopoiesis, and ultimately the activation of the adaptive immune system.
The intracellular signaling cascades associated with PRR signaling are subject to a stringent set of checks and balances that are necessary to avoid excessive inflammation. These negative regulatory mechanisms are typically self-generated and occur through negative feedback loops to restore homeostasis and promote resolution. In this review, we focus our discussion on a selection of mechanisms that converge to negatively regulate NF-B signaling. As a master regulator of gene transcription, targeting NF-B signaling is a highly effective strategy used by the cell to modulate significant and diverse biological processes, including inflammation. Indeed, there is a reinvigorated interest in better defining mechanisms associated with the negative regulation of NF-B signaling, as evidenced by the increasing number of recent publications and reviews on this topic. For example, an excellent review by Afonina et al. was recently published that focused on the negative regulation of NF-B signaling and the NLRP3 inflammasome. 3 Here, we do not significantly cover NLRP3 inflammasome regulation or modulation. However, we do discuss several similar posttranscriptional and posttranslational mechanisms associated with NF-B regulation. We further expand our discussion to provide a more extensive overview of both canonical and noncanonical NF-B signaling and focus on additional mechanisms associated with pathway regulation not extensively included in other previous reviews on this topic. Together, we believe that the current review is an excellent complement to previous works focused on the regulation of NF-B signaling and the individual molecules discussed. In the course of assembling this review, we identified over 200 proteins that have the ability to target and attenuate NF-B signaling. This high level of regulation is likely due to the vast and essential biological functions associated with NF-B signaling in different cell-type and temporal-specific situations, and serves to underscore this particular pathway's importance and complexity. For brevity, we chose to focus this work on several archetypical mechanisms that broadly regulate this signaling cascade at the transcriptional, posttranscriptional, and posttranslational levels in order to provide a concise overview of a selection of major regulatory elements.
Inflammation and NF-B signaling
NF-B is an evolutionarily conserved transcription factor found in species ranging from Drosophilia to humans, which underscores its critical role in the host immune response. The last 3 decades of research have contributed greatly to our understanding of NF-B.
NF-B functions as a prominent inducible transcription factor that regulates the immune system. 4 Due to its diverse and broad biological functions, strict regulation of NF-B signaling is paramount to proper tissue allostasis. When NF-B signaling is aberrant, several maladies can ensue, such as susceptibility to infections, autoimmunity, and cancer. 5, 6 Thus, as with many major signal transduction pathways, several mechanisms tightly regulate NF-B signaling and maintain the proper balance of activation and repression.
NF-B in mammals consists of a total of five proteins that are predominantly present in an inactivated state in the cytosol as either homo-or hetero-dimers that include: RelA (p65), RelB, c-Rel, p105, and p100. The p105 and p100 proteins are unique because they must undergo posttranslational processing through the proteasome to form the active subunits, p50 and p52, respectively. 4 All isoforms contain a common Rel homology domain, which is responsible for DNA binding and binding to the cytosolic inhibitory proteins, termed Inhibitor of -B (I B). 7 Several families of cellular receptors signal through NF-B to initiate gene transcription and are known to coordinate signaling through either the canonical NF-B pathway or the noncanonical NF-B pathway (which is also termed the "alternative" NF-B pathway). Molecules that signal via the canonical NF-B pathway include cytokines, such as TNF, IL-1 , and the majority of PRRs. 4 The noncanonical pathway is initiated by a much smaller repertoire of molecules that are members of TNF family, such as CD40, B-cell activating factor (BAFF), and lymphotoxin beta (LT-). 8 
The canonical NF-B signaling pathway
Convergence on the canonical NF-B signaling pathway occurs through the activation of several different families of receptors (i.e. TNFR, TLRs, NLRs, IL-1R). 9 As a classical example of canonical activation, we will focus on MyD88-dependent TLR signaling (Fig. 2) , a process that occurs for the IL 1 receptor (IL-1R) and all TLRs with the exception of TLR3. 10 IL-1/TLR signaling commences via binding of their respective ligands. Engagement of a PAMP to an extracellular TLR (i.e. TLR1, TLR2, TLR4, TLR5, TLR6) induces a conformational change and hetero-or homo-dimerization of the TLR. Dimerization leads to a change in conformation of the receptor, followed by recruitment of adaptor proteins to the toll/interleukin receptor (TIR) domain of the TLR. The adaptor molecule MyD88 is recruited to extracellular dimers composed of TLR5 receptors, whereas Mal followed by MyD88 are recruited by TLR1/TLR2, TLR2, TLR2/TLR6, TLR4 dimers. [11] [12] [13] [14] [15] [16] MyD88 acts as a protein scaffold, as it contains both a TIR domain and a death domain (DD) in its protein structure. The DD of MyD88 recruits interleukin receptor associated kinase (IRAK) IRAK-4, followed by IRAK-1, all in a helical assembly to form a Myddosome complex. 17, 18 The close spatial proximity of IRAK-4 to IRAK-1 allows for IRAK-1 to become rapidly phosphorylated by IRAK-4, and then undergo 34 and future studies will aid to further define this link.
The noncanonical NF-B signaling cascade
The activation of the noncanonical or alternative NF-B signaling cascade is tightly regulated and has a much smaller group of ligands and receptors that can induce its activation. 8 Members of the TNF/TNFR superfamily, which include the lymphotoxin receptor (LT R), CD40, B-cell activating factor receptor (BAFFR), receptor activator of NF-B, TNFR2, and CD27 have all been shown to signal through the noncanonical pathway. 8 Upon ligation of TNF family members to their receptors, the TRAF2-TRAF3-cIAP1/2 E3 complex is recruited to the receptor. 8 This recruitment leads to accumulation of TRAF2 molecules, allowing TRAF2 to shift cIAP1/2 ′ s Lys-48 Ub ligase activity toward TRAF3 via Lys-63 polyubiquitination of cIAP1/2. 8, 35 When TRAF3 is modified via this mechanism, it ultimately leads to proteasomal degradation of TRAF3, allowing for accumulation of MAP3K14 (also commonly known as NF-B inducing kinase (NIK)), resulting in increasing the levels of cytosolic NIK. 8 Mechanistically,
in an unstimulated state, TRAF3 acts as a binding partner for NIK bringing it close to the cIAP1/2 E3 ligase complex, which in this case leads to its degradation. 36, 37 NIK is essential for the processing of p100 into active p52, 7, 8 which is a defining feature of the noncanonical NF-B signaling pathway (Fig. 3) . However, NIK has also been shown to phosphorylate IKK , which can act as a secondary kinase that mediates the activation of p100. 38 For this to occur, NIK must be present in relatively high concentrations inside the cell before interacting with IKK . Thus, stabilization of NIK results in its accumulation and interactions with IKK , culminating in phosphorylation and activation. 8, 38 It is thought that IKK -mediated phosphorylation of p100 occurs on Ser-872 in vitro and Ser-866 and 870 in vivo. 8 While the cause of this discrepancy is currently unclear, presumably, IKK acts as a site-specific kinase for p100. This phosphorylation step targets the Cterminal inhibitory domains (the PID and the ankyrin repeat domain) of p100 for degradation via the proteasome. 8 Ankyrin repeat domains (ARDs) have been shown to mask the nuclear localization sequence (NLS) of I B and interestingly, p100's phosphorylation site contains a sequence similar to I B . 8, 39 Therefore, disruption of the ARD of p100 via proteasomal degradation may lead to unmasking of the NLS and subsequent translocation of p52/RelB to the nucleus. 39 Once in the nucleus, p52/RelB drives the transcription of a limited repertoire of genes, including CCL19, CCL21, CXCL12, and CXCL13. In contrast, when the TNFR family members are unstimulated, NIK is instead degraded via Lys-48 polyubiquitination. 8 Consequently, IKK will not become activated and phosphorylate p100. Thus, in this scenario, the NF-B dimer cannot enter the nucleus and initiate transcription of target genes. Due to its essential function, NIK represents a "bottleneck" in the noncanonical NF-B signaling cascade and is frequently targeted by mechanisms that have evolved to negatively regulate this alternative pathway.
TRANSCRIPTION INHIBITION
The canonical and noncanonical NF-B signaling cascades are complex cIAP2
p52 F I G U R E 3 Noncanonical NF-B signaling pathway. When unstimulated, only small amounts of NIK are expressed, which are immediately degraded by the TRAF3-TRAF2-cIAP1/2 complex. TRAF3 binds to NIK while TRAF2 acts as a bridge between TRAF3 and cIAP1/2, allowing for cIAP1/2-mediated lysine-48 polyubiquitination of NIK and subsequent proteasomal degradation. However, when a TNFR family member is activated, the TRAF3-TRAF2-cIAP1/2 complex is recruited to the receptor. This leads to an accumulation of TRAF2, which results in cIAP1/2 lysine-63 polyubiquitination and a shift in ligase activity of cIAP1/2 toward TRAF3 via lysine-48. The polyubiquitination and degradation of TRAF3 leads to an increase in NIK. Stabilized NIK is then free to interact with and phosphorylate IKK . p100 is phosphorylated by active IKK , further processed by lysine-856 polyubiquitinatation and degraded, leaving active p52. p52 and RelB are then free to translocate into the nucleus heterodimers results in the concealment of the NLS on RelA (p65), thus keeping NF-B heterodimers mainly contained in the cytosol under normal conditions. 9, 40 Following activation of the canonical NF-B pathway, the IKK complex participates in NF-B activation by phosphorylating I B on two key serine residues (Ser-32 and Ser-36). 41 Phosphorylation of I B on these particular serine residues is an irreversible tag that results in further processing by polyubiquitination and degradation by the proteasome. Once I B is degraded by the proteasome, the nuclear import signal on p65/p50 heterodimers is no longer blocked, allowing for NF-B translocation to the nucleus to regulate gene transcription. 42 
IRAK-M
There are four IRAK family members in mammals: three of which are known as IRAK-1, IRAK-2, and IRAK-4. These three family members act as positive regulators of NF-B signal transduction. [43] [44] [45] [46] One family member, IRAK-3 or IRAK-M, is unique from the other family members in both structure and function, most notably acting as an inducible negative regulator of the canonical NF-B signaling pathway. 47 All four IRAK family members share an N-terminal DD that is important for homotypic protein-protein interactions with either MyD88 or with other IRAK family members. Likewise IRAK-1,-2, and -M contain a unique C-terminal domain that contains TRAF6-binding motifs. 48 Together, these domains are essential for signal transduction and all IRAK proteins contain kinase domains. 49 IRAK-1 and IRAK-4 were first described as being the only functional kinases in the family, with IRAK-2 and IRAK-M being inactive or pseudo-kinases. [43] [44] [45] 47 These designations were originally based on amino acid sequence predictions. 50 There are specific residues in the sequence of the kinase domain that are invariant for kinase function and these include residues in the kinase subdomain VIb, which are known as the HRD and DFG motifs. 50, 51 The motifs con- signaling. However, with in vitro kinase assays, human IRAK-M was demonstrated to have very weak intrinsic kinase activity, especially compared to IRAK-1. 52 Further, murine IRAK-M was shown to contain detectable kinase activity; albeit, at a lower level when compared to the robust auto-phosphorylation of human IRAK-1. 53 These data suggest that the auto-phosphorylation, and therefore the kinase activity of IRAK-M is negligible for its function; however, it is tempting to speculate that IRAK-M may indeed function as an active kinase on a currently unknown cellular substrate following its induction.
Despite these initial findings and speculation, the prevailing literature suggests that IRAK-M functions as a negative regulator of NF-B signaling following TLR activation. These data are based on findings utilizing genetically modified mice with targeted deletions of the Irak-m gene. 47 The Irak-m gene contains 12 total exons and in order to define the role of IRAK-M, exons 9-11 were targeted for deletion. 47 These exons encode the amino acids predicted to constitute the putative kinase domain. Full-length IRAK-M was not detected when a Western blot was performed with an antibody specific for the C-terminus of IRAK-M. 47 Using these genetically modified animals, Irak-m was found to be induced by NF-B, along with I B and A20 following TLR stimulation, suggesting a negative feedback mechanism. Subsequent coimmunoprecipitation experiments demonstrated that IRAK-M has the capacity to bind to TRAF6, leading to the current model that IRAK-M functions to inhibit IRAK-1 and TRAF6 interactions, which in turn inhibits downstream NF-B activity. 47 The expression of IRAK-M can be induced by other transcription factors, such as C/EBP, Smad4, AP-1, and CREB, 54 suggesting additional functions beyond the feedback mechanism currently described. Phenotypically, Irak-m −/− mice do not display any abnormal fetal or postnatal development, but do develop osteoporosis later in life due to hyperactive osteoclast activity. 47, 55 These Irak-m −/− mice were instrumental in defining IRAK-M as a negative regulator of NF-B signaling and have been widely utilized to define its function. For example, consistent with increased NF-B signaling, Irak-m −/− bone marrow derived macrophages (BMDMs) display impaired endotoxin tolerance and hyper-production of inflammatory cytokines (i.e. IL-6, TNF, and IL-12p40) following TLR stimulation with specific PAMPS, as well as, L. monocytogenes and S. typhimurium. 47 Consistent with the ex vivo BMDM studies, Irak-m −/− mice were found to display enhanced small intestinal inflammation following in vivo exposure to S. typhimurium. 47 Interestingly, in these initial studies, Irakm −/-mice do not display enhanced morbidity or mortality following infection, despite the increased inflammation. 47 These findings are consistent with a more recent study that showed the Irak-m −/− mice are protected in models of experimental colitis and colitis-associated tumorigenesis. 56 Mice lacking IRAK-M were found to have a robust immune response to bacteria translocating from the lumen following chemical induced damage to the intestinal epithelial cell barrier. 56 The attenuation in pathogenesis was associated with large expansions of gastrointestinal associated lymphoid tissue, increased neutrophil function, and enhanced T-cell recruitment. 56 Complementary data revealed that the gastrointestinal (GI) tract of the Irak-m −/-mice had a lower total colonic bacterial load compared to wild-type counterparts, which could also contribute to attenuation of disease pathogenesis. 57 Mechanistically, these data suggest the immune system in Irak-m −/− animals is primed and more prone to a robust inflammatory response.
In the GI tract, this improves the efficiency of the host response to pathogenic and commensal components of the host microbiome that drive disease processes.
It should be noted that while the consensus data identifies IRAK-M as a negative regulator of NF-B signaling, contrary data suggests a possible alternative mechanism. Recently, it was demonstrated that IRAK-M participates in TAK-1 independent NF-B activation downstream of TLR7 through MEKK3. 58 With the use of IRAK-1/IRAK-2 double-deficient mice and IRAK-1/-2/-M triple-deficient mice, this study demonstrated that under highly specific conditions, IRAK-M functions in the absence of IRAK-1 and IRAK-2 and can actually activate NF-B signaling. 58 Mechanistically, IRAK-M interacts with IRAK-4 to form an IRAK-M myddosome complex in the absence of both IRAK-1 and IRAK-2 that modulates NF-B signaling through TAK-1 independent mechanisms. 58 While these data are certainly intriguing, the study ultimately concluded that IRAK-M exerts an inhibitory effect under normal conditions by indirectly inducing inhibitory proteins (A20, SHIP-1, SOCS1, and I B-). 58 Further clouding mechanistic insight, it has recently been revealed that the original Irak-m −/− mice commonly used to characterize this protein may actually contain a truncated version of IRAK-M. 56 Detailed sequencing analysis of the Irak-m gene product was conducted following TLR stimulation of BMDM from genotype confirmed Irak-m −/− mice. 56 Under these conditions, a splice variant of the Irak-m gene was identified that resulted from the splicing of exon 8 with exon 12, in essence splicing around the neo cassette. 56 This type of splice variant is a common occurrence in genetically modified animals where functional domains are targeted, as opposed to the gene's start site. Typically, these truncated proteins are dysfunctional and degraded by the cell, which preserves the knockout status of the animals. It is also important to note that the truncated IRAK-M protein has not yet been detected in situ and may not exist in vivo. 56 However, overexpression of Irak-m rΔ9-11 and functional studies using the recombinant protein revealed that this truncation mutant is significantly more potent at activating NF-B signaling then the wildtype version. 56 Considering these data, we agree with the consensus findings that should also be pointed out that the history of IRAK-M is similar to that of IRAK-2, which was first believed to function as an inactive pseudokinase. 50 However, it was later determined that IRAK-2 function was independent of IRAK-1 and plays a critical role in sustaining the late phase of NF-B signaling through potentially functioning as an active kinase. 46 Future studies will indicate whether our interpretation into the function of IRAK-M will be modified, as we have previously seen with IRAK-2.
Regulatory NLRs
Members of the nucleotide-binding domain and leucine rich repeat containing (NLR) family function through the formation of multiprotein complexes and are potent cytosolic regulators of diverse biochemical pathways. The best known and characterized members of this family include proteins that form inflammasomes. 59 However, other subgroups exist beyond these inflammasome-forming NLRs that function as regulators of diverse biochemical signaling cascades. 60, 61 These regulatory NLRs either positively or negatively modulate signaling pathways directly or following the activation of other PRRs. 60, 61 Negative regulatory NLRs, such as NLRP12, NLRX1, and NLRC3, are the least defined family members. While the mechanisms and pathways targeted by these three NLRs vary, all seem to converge on the NF-B signaling cascade.
Of the three negative regulatory NLRs, NLRP12 is the most studied and was one of the first NLRs to be functionally characterized. These interactions result in the degradation of NIK, which leads to the subsequent inhibition of p100 cleavage to p52. NLRP12 inhibits IRAK-1 phosphorylation in a similar mechanism to attenuate the canonical NF-B signaling pathway 71, 74, 77 (Fig. 4) . Beyond these direct mechanisms, NLRP12 may also indirectly attenuate NF-B signaling by also targeting components of the ERK signaling pathway. 66, 71 However, the exact mechanism of NLRP12 inhibition of ERK signaling and the relationship with NF-B signaling has yet to be fully resolved. 66, 71 Unlike other NLR family members, NLRX1 has an undefined Nterminal domain and has an intimate relationship with the mitochondria. This unique NLR was originally found to negatively regulate type-I interferon signaling through interactions with the mitochondria antiviral signaling protein. [80] [81] [82] [83] [84] In these original studies, NLRX1 was shown to curtail inflammation and promote resolution following virus infection through inhibiting RIG-I-specific signaling. 81, 83 However, beyond the attenuation of IFN signaling, and similar to NLRP12, NLRX1 also negatively regulates NF-B signaling through interactions with TRAF proteins (Fig. 4) . Specifically, NLRX1 associates with TRAF6 and IKK though an activation signal-dependent mechanism. 82 NLRX1 interacts with TRAF6 until stimulation, where NLRX1 is rapidly ubiquitinated and disassociates from TRAF6 allowing it to bind to the IKK complex. 82 This ultimately results in the inhibition of canonical NF-B signaling. 82 Similar to NLRX1, NLRC3 has also been shown to negatively regulate NF-B and IFN-I signaling. 85, 86 Of the regulatory NLRs, 87 In the NF-B pathway, NLRC3 appears to delay the degration of I B to temper TLR signaling through interactions with TRAF6. 85 While our understanding of NLRC3 is significantly lacking compared to many of the other NLR family members, the characterization of this protein has yielded significant mechanistic insight pertinent to the other negative regulatory NLRs. Mechanistic studies with NLRC3 revealed prevalent interactions with TRAF proteins and support the emerging hypothesis that members of the negative regulatory NLR subgroup function through the formation of a multiprotein "TRAFasome" complex to negatively regulate NF-B signaling. 85 These data are consistent with the findings associated with NLRP12 (TRAF3) and NLRX1 (TRAF6) and provides some mechanistic insight regarding the multiple pathways that seem to be modulated by members of this NLR subgroup. Continued systematic study will be necessary to better characterize the formuation of this complex and identify additional interacting proteins. Two of these splice variants have been shown to negatively regulate NF-B signaling. One of these isoforms, Irak2c, was found to contain a putative NF-B-binding site not present in other Irak2 isoforms. 89 Thus, this isoform is suspected to exert an inducible negative feedback effect on the NF-B signaling cascade. 89 It should be noted that similar isoforms have not been characterized for human IRAK2. 89 
POSTTRANSCRIPTIONAL INHIBITION

microRNA
In addition to alternative splicing strategies, targeting RNA for degradation is also a highly effective negative feedback mechanism to modulate NF-B signaling. MicroRNAs (miRNAs) are a particular class of RNA with regulatory function that act in this manner. These miRNAs robustly regulate the stability and translation of mRNA transcripts encoding key components of the NF-B signaling cascade. Prior to processing, miRNAs are transcribed from long primary transcripts, known as pri-miRNA. Following pri-miRNA transcription, hairpin-loops will form in the pri-miRNA that are then recognized by the enzyme Dicer, which aids in the further processing and cleavage of the pri-miRNA into the mature miRNA. 90 Once mature, the miRNA is loaded into the RISC complex and modulates gene silencing through posttranscriptional mechanisms via antisense base pairing to coding mRNA transcripts. Over 1000 human miRNAs have been identified, which makes this class of regulatory molecules one of the most abundant available to the cell to control signaling. 91 Indeed, a brief search of NF-B pathway components for this review identified multiple miRNAs for almost every step in the cascade, including those shown in Fig. 4 . Due to the abundance of this class of regulatory molecules and the diversity of the respective targets, deciphering their biological functions and physiological relevance is essential. Of these miRNA, three have been well described in the context of NF-B signaling, miR-146, miR-21, and miR-155 and are described in further detail below.
MicroRNA-146 (miR-146) is particularly relevant in macrophages
and has two variants, miR-146a and miR-146b. These variants are strongly induced by NF-B following TLR4 engagement by LPS and following pathogen encounter. 92 Once induced, miR-146 binds to the 3 ′ UTR of both IRAK-1 and TRAF6, either promoting the degradation of their respective mRNA or physically preventing their translation. 93 The latter mechanism is supported by overexpression studies, where miR-146a/b prevented protein translation of IRAK-1 and TRAF6, with no observable decrease in mRNA transcripts. 93 This binding was sufficient to inhibit MyD88-dependent NF-B signaling. 92 Additional studies using a miR-146a −/− mouse, further confirmed these findings. 94 These mice display a vigorous hyperinflammatory response to low doses of LPS and most succumb to endotoxic shock at higher doses of LPS more rapidly than wild-type control animals. 94 Further, mice that are aged beyond 6 months develop severe multiorgan inflammation, tumorigenesis, and eventual death. 95 These miR-146a −/− mice develop malignancies that are consistent with constitutive NF-B signaling, including lymphoma and myeloid sarcoma, 60 and deletion of the p50 subunit of NF-B resulted in suppression of these diseases. 95 It is interesting to note that both miR-146a/b and IRAK-M negatively regulate NF-B by interfering with IRAK-1 and TRAF6. This demonstrates the importance of both IRAK-1 and TRAF6 as essential signaling nodes for NF-B activation. Further, overexpression and hyperactivity aberrancies in IRAK-1 contribute to myelodysplastic syndrome and overexpression of TRAF6 results in osteosarcoma, 96, 97 which is also consistent with the phenotype of the miR-146a −/− mice and loss of negative regulation in the NF-B pathway.
Similar to miR-146, miR-21 also regulates NF-B signaling to limit excessive inflammation through a negative regulatory feedback loop. 98 Following TLR4 activation, miR-21 directly binds to the 3 ′ UTR of programmed cell death-4 (PDCD4) and thereby counteracts the effects PDCD4. 99 PDCD4 functions to assist in the activation of NF-B and augments IL-6 production, while also limiting the production of the anti-inflammatory cytokine IL-10. 98 In this regard, PDCD4 acts as a molecular switch that tips the balance toward a proinflammatory microenvironment. Therefore, by opposing the effects of PDCD4, miR-21 attenuates persistent inflammation, by negatively regulating NF-B and IL-6 production, while simultaneously augmenting the production of IL-10. 98 Consistent with this mechanism, Pdcd4 −/− mice display resistance to the lethal effects of endotoxic shock when administered LPS, compared to wild-type controls. 98 Cell type specific differences for the function of miR-21 have been described. 98, 100 In RAW 264.7 cells (macrophages) miR-21 acts as a negative regulator of NF-B when stimulated with LPS. 98 Alternatively, in a cellular transformation model driven by estrogen receptor-Src in MCF10A cells (mammary gland epithelial cell), miR-21 is induced by STAT-3. In the MCF10A model, miR-21 directly inhibits PTEN in the PI3K-Akt pathway and results in the activation of NF-B signaling necessary to maintain the transformed state of these cells. 101 Genetic ablation of miR-21 in mice has demonstrated both pro-and antioncogenic roles, 102, 103 perhaps due to the cell type specific effects discussed above. In one model, miR-21 −/− mice display reduced tumorigenesis when skin cancer is induced by chemical means. 102 This was attributed to increased apoptosis, decreased proliferation of epithelial keratinocytes, and an overall inhibition of the Ras-pathway. 102 Pam3CSK4. 109 Proximal signaling of either the MyD88-dependent or TRIF-dependent pathways leads to miR-155 induction; whereas, inhibition of the JNK pathway prevents the induction of miR-155 when stimulated. 109 Functionally, miR-155 directly binds to the 3 ′ UTR of the inositol phosphatase SHIP1 and represses SHIP1 function. 110 In BMDMs deficient in miR-155, SHIP1 levels are significantly increased 24 hours after treatment with LPS. 110 These data illustrate the importance of miR-155 in the JNK and AKT signaling pathways following LPS exposure. However, the role of miR-155 on the NF-B signaling pathway appears to be context dependent. When induced in Kupffer cells, in a mouse model of liver disease driven by chronic alcohol consumption, miR-155 was shown to decrease the levels of IRAK-M, SHIP1, PU.1, and increase TNF. 111 Likewise, overexpression of miR-155 in mouse B cells, utilizing E -miR155 transgenic mice, produce more TNF when challenged with LPS and are more susceptible to death from endotoxic shock. 112 In this later study, miR155 was found to modulate NF-B signaling through targeting IKK , FADD, and RIPK1 transcripts. 112 Mice lacking miR-155 have been generated and under typical physiologic conditions, these animals display normal growth and development. 113 However, in a chemically induced model of colitis utilizing DSS, loss of miR-155 contributes to resistance and protection. 114 This protection from colitis was attributed to a reduction in frequency of CD4+ T cells. 114 Likewise, diminished Th1 and Th17 cell numbers were observed, which also likely attenuated colitis progression. 114 It is worth noting that the overexpression of miR-155 skews T-helper cells toward a Th1 phenotype and proper antigen presentation from dendritic cells is lost in the absence of miR-155. 107, 115 In hematopoietic stem cells, sustained expression of miR-155 results in severe myeloproliferative disorder. 116 When taken together, these data suggest that loss of miR-155 actually results in a global attenuation of immune cell numbers resulting in reduced inflammation and malignancy.
RNA-binding proteins
In addition to miRNA, RNA-binding proteins (RBPs) are also highly effective regulators of NF-B signaling. 3 These proteins act by binding to specific RNA molecules and recruiting catalytic proteins, which perform a diverse range of functions to modulate the target RNA, such as facilitate alternative splicing, polyadenylation, assist with mRNA transportation, and degradation. 3, 117 Together, these posttranscriptional strategies offer a rapid and robust mechanism to modulate NF-B signaling.
The degradation process is one of the most critical functions facilitated by RBPs. In the context of NF-B regulation, one of the best-characterized RBPs is Tristetraprolin (TTP). TTP is considered a prototypic member of the RBPs and regulates NF-B signaling by facilitating mRNA degradation. 3, 118 Specifically, TTP binds to mRNAs rich in AU-rich elements (AREs), which includes TNF and IL-23, and induces degradation. 119 TTP-deficient mice develop hyperinflammatory profiles that include arthritis, dermatitis, cachexia, and myeloid hyperplasia. 119, 120 Macrophages derived from TTP-deficient mice have increased production of TNF after stimulation with LPS. 119 This increase in TNF is associated with improved TNF mRNA integrity directly associated with TTP deficiency. 119 While increased TNF would be anticipated to stimulate both canonical and noncanonical NF-B signaling, luciferase reporter assay data suggests that TTP may actually attenuate the canonical NF-kB cascade and this attenuation appears to occur downstream of p65. 118 In these studies, TTP does not affect TNF-induced I B degradation. 118 Rather, TTP-mediated inhibition occurs at the level of nuclear translocation, as truncation of the NLS on p65 removed the attenuation of luciferase activity. 118 Thus, TTP may impair the nuclear translocation of p65 via an ARE-independent mechanism. 118 TTP is not the only RBP that is known to negatively regulate inflammation. Regnase-1 was discovered to be important for the negative regulation of inflammation in a similar manner to TTP. Specifically, mice that lacked regnase-1 show signs of hyper-inflammation and autoimmunity, such as decreased survival rates, hyperimmunoglobulinemia, and increased tissue infiltration of immune cells. 121 In addition, peritoneal macrophages from Regnase-1 −/− mice show increased expression of proinflammatory cytokines, such as IL-6 and IFN , after stimulation with TLR agonists. 121 The increased expression of proinflammatory cytokines is associated with regnase-1 degradation of NF-B target genes via its intrinsic RNase activity. 121 Regnase-1 contains RNase activity and exerts its effects through the AREs in the 3 ′ UTR regions of target mRNAs. 121 Mechanistically, it was shown that stem-loop (SL) structures are required for regnase-1 to bind with the target mRNA, but is not required for degradation. 122 Studies using Regnase-1 −/− macrophages revealed that regnase-1 works on translationally active mRNAs. 122 Specifically, regnase-1 knockdown using siRNA in HeLa cells followed by treatment with IL-1 , revealed increased Il6 and Ptgs2 mRNA expression in polysome fractions compared with the control cells. 122 This has led to the suggestion that regnase-1 is involved in regulating early inflammatory steps and likely involves either direct or indirect inhibition of NF-B signaling. In addition to its RNase activity, regnase-1 has also been reported to show deubiquitinating enzyme (DUB) activity that can act to attenuate NF-B activation. A study using Raw264.7 transfected with regnase-1 (or control vector) and stimulated with LPS showed that regnase-1 expression partially blocked IKK phosphorylation. 123 Further investigation revealed that regnase-1 cleaved K63-linked poly-Ub chains on TRAF2 and TRAF6. 123 NF-B activation has been shown to affect regnase-1 expression as well. As stated above, LPS stimulation in macrophages leads to an increase in regnase-1 expression. However, it was also found that regnase-1 shows similar expression kinetics, to that of I B when cells were stimulated with LPS. This lead to the hypothesis that regnase-1 may be controlled by modification via TLR-mediated NF-B activation. 124 Specifically, stimulation of TLRs in macrophages showed a disappearance of regnase-1 via immunoblot. 124 Further experiments revealed that IKK phosphorylates regnase-1 leading to its ubiquitination and degradation via the proteasome. 124 Together, these data clearly show that the two most studied RBPs, TTP, and regnase-1, are tightly linked to NF-B activation and act as important players of negative feedback in this pathway to help control inflammation. However, more work is needed to better define mechanisms for these proteins.
In contrast to TTP and regnase-1, the RBP Roquin has been shown to target translationally inactive mRNAs. 122 This is interesting because both Roquin and regnase-1 affect a common stem loop structure, but in different subcellular locations. 122 Further evidence of Roquin's ability to regulate inflammation has been shown in Roquin-1-deficient mice, as these animals develop severe multiorgan hyperinflammation. 125 Early experiments showed that Roquin targeted the T-cell inducible costimulator (ICOS) mRNA in the 3 ′ UTR, thus regulating its expression via degradation. 126 Subsequent studies revealed that Roquin can inhibit Th17 differentiation and that this inhibition can be regulated via MALT1 (mucosa-asociated-lymphoid-tissue lymphomatranslocation gene 1). 127 Specifically, in CD4 + T cells that were treated with PMA and ionomycin, Roquin is cleaved and this cleavage is blocked by MALT1 inhibitors. 127 Thus, Roquin also has the potential to attenuate NF-B signaling, albeit through targeting translationally inactive mRNAs.
POSTTRANSLATIONAL INHIBITION
Posttranslational modification of key proteins is another well-defined mechanism associated with the regulation of NF-B signaling.
Common modifications include phosphorylation, glycosylation, ubiquitination, methylation, acetylation, and proteolysis and many of these processes occur in a gene transcription independent manner that allows for rapid and specific modulation of complex biological signaling cascades. Of these modifications, phosphorylation, and ubiquitination are commonly observed in the NF-B signaling cascade. Phosphorylation is one of the best-studied posttranslational modifications and is commonly considered to be an activating signal in the NF-B cascade.
This process is typically reversible, allowing a high level of temporal or tunable control, and usually occurs on serine, threonine, or tyrosine residues. In the NF-B signaling pathway, phosphorylation can induce conformational changes in proteins such as IRAK and the IKK kinases, resulting in the release of auto-inhibition and increased enzymatic activity. 3 Conformation changes associated with phosphorylation can also promote or facilitate protein-protein interactions, such as those associated with I B or caspase-recruitment-domain proteins. 3 Thus, phosphatases can function as negative regulators of NF-B signaling by dephosphorylating select proteins in the cascade. Likewise, while phosphorylation is commonly considered an activating signal, phosphorylation of inhibitory proteins can result in a net inhibitory effect on the signaling cascade. For example, IKK phosphorylation of key components of the A20 Ub-editing complex results in activation and subsequent attenuation of NF-B signaling. 128 While phosphorylation is typically considered to be an activating posttranslational modification, ubiquitination can be either an activating or an inhibitory signal, depending on the types of poly-Ub linkages.
Ubiquitin is a small 8.5 kDa peptide found in eukaryotic cells that can be covalently attached to proteins to regulate their function posttranslationally. This is accomplished via the addition of poly-Ub chains to amino acid residues on target proteins. Ub itself contains seven different lysine residues, and the particular lysine chain that is utilized to make the poly-Ub chain determines the regulatory status of the protein. The seven-lysine residues found on Ub are Lys-6, Lys-11, Lys-27, Lys-29, Lys-33, Lys-48, and Lys-63, with Lys-48 and Lys-63 linkages being the best characterized in the context of NF-B regulation. 129, 130 Generally, when a target protein is modified by Lys-48 linked polyubiquitination, this serves as a molecular tag on the protein for recognition and further destruction by the 26S proteasome. 131, 132 Additionally, Lys-63 linked polyubiquitination is a posttranslational modification that generally results in the activation of tagged proteins. 129 Similar to phosphorylation, ubiquitination is also reversible and is tightly controlled by a balance between the opposing actions of E3 Ub ligases and DUBs. 3 In the NF-B signaling pathway, Ub moieties can serve as docking regions for proteins with Ub-binding domains, such as NEMO recruitment to proteins modified by Lys-63 linked poly-Ub chains. 3 Likewise, ubiquitination can serve as a signal to break down specific proteins by marking them for proteasomal degradation, for instance Lys-48 polyubiquitination of I B . 3 Thus, mechanisms capable of manipulating ubiquitination are typically potent regulators of NF-B signaling.
A20
A20 or TNF alpha-induced protein 3 is a protein that is rapidly induced by NF-B and functions through a feedback mechanism to halt the conjugating enzymes Ubc13 and UbcH5c. 136 The mechanism associated with this disruption is associated with A20 triggered ubiquitination of Ubc13 and UbcH5c, resulting in proteasome-dependent degradation. 136 As a DUB, A20 appears to preferentially deubiquiti- (Fig. 5 ).
The importance of A20 as a key negative regulator of NF-B signaling was demonstrated with the use of A20 knockout mice. 133 In the absence of A20, mice display a significant inflammatory phenotype in the liver, intestine, bone joints, skin, and kidney. 133 Furthermore, severe cachexia occurs in several organs and mortality commences postnatally within a few weeks of age. 133 This increase in morbidity and mortality can be further augmented when mice are given low doses of TNF or LPS. 133 A20 does not appear to be crucial for fetal development, because mice display an appropriate
Mendelian ratio when born. It was demonstrated in mouse embryonic fibroblasts (MEFs) that in the absence of A20, NF-B transcriptional activity is sustained and I B mRNA is transcribed with similar, even possibly increased levels, compared to wild-type animals. However, I B protein levels do not rebound following TNF treatment. 133 This was attributed to the continued activity of the IKK complex, because in the presence of the proteasome inhibitor MG-132, I B levels were restored. Furthermore, it was demonstrated that I B was continually phosphorylated by the IKK complex following translation, which resulted in its constant degradation in A20 null cells. 133 Similarly, A20-Tnf and A20-Tnfr1-deficient mice also develop severe spontaneous inflammation, with evidence supporting roles in both innate and adaptive immune system functions. 139 LPS stimulated A20-Tnf double-deficient BMDMs display a strong production of IL-6 and nitric oxide (NO) compared to wild-type mice. These levels were attenuated compared to A20-deficiency alone. 139 Likewise, robust inflammation was observed in A20-Rag1 double knockouts, suggesting that A20 also plays a prominent role in negatively regulating immune pathways beyond those regulated by TNF and the adaptive immune system. 139 In addition to TNF signaling, A20 was also demonstrated to robustly regulate TLR signaling. Myd88-A20 doubledeficient mice do not develop severe multiorgan inflammation and cachexia, as seen in A20 knockout mice alone. Thus, if TLR-mediated NF-B activation is nonfunctional, then there is a reduced need for A20 inhibition.
Similar to the mouse studies, mutations in the human gene encoding A20 TNFIAP3, are strongly linked with a variety of hyperinflammatory, autoinflammatory, and malignant diseases in patients. 140 These diseases include systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and type 1 diabetes. 140 In general, cells from patients with mutations in TNFIAP3 show increased degradation of I B , p65 nuclear translocation, and subsequent expression of a range of proinflammatory cytokines associated with canonical NF-B signaling. 141 Interestingly, the host microbiome significantly contributes to the pathogenesis of the majority of the diseases linked to A20 dysfunction and proper NF-B signaling is a key element required to keep the balance between commensal and pathogenic microbes, especially in the gut. 142 Thus, it is possible that dysfunctional A20 regulation of NF-B signaling could contribute to dysbiosis and disease in human patients. Indeed, support for this hypothesis has already been reported in mouse models where spontaneous hyperinflammation in chimeric mice reconstituted with A20 −/− bone marrow were rescued using antibiotic microbiota ablation. 143 While there is still much to learn regarding the function of A20, together these mouse and human studies emphasize the importance of this key molecule in regulating NF-B signaling in a variety of biological and clinically relevant conditions.
CYLD
CYLD is a constitutively expressed DUB that was originally described as a tumor suppressor gene. 144 Loss of function of CYLD in humans is associated with familial cylindromatosis, which are multiple benign skin cancers usually localized to the face and neck. 144 Additional mechanistic studies revealed that loss of CYLD contributes to an overall cellular resistance in apoptosis, 145 which likely contributes to cancer pathogenesis. CYLD is a member of the Ub-specific protease family, which represents the largest family of DUBs in the human genome. 146 As a bona fide cysteine protease, CYLD cleaves Lys-63 linked chains of poly-Ub on target proteins. 147 This serves as a repressive function because addition of poly-Ub on Lys-63 is generally a posttranslational modification that leads to increased activity of modified proteins. Interestingly, in addition to Lys-63 mediated de-ubiquitination, CYLD has the ability to de-ubiquitinate via linear Ub chains. 148 It is interesting to note that CYLD and A20 cleave Ub chains on several of the same substrates that participate in the signal transduction cascade in the NF-B pathway, including but not limited to RIP1, IKK , TRAF2, and TRAF6 142, 145, 149, 150 (Fig. 5 ). This overlap in negative regulatory function demonstrates the importance of signaling molecules, such as TRAF6, as primary nodes in the induction of the inflammatory cascade. The posttranslational modification of several of the same molecular targets between A20 and CYLD could be due to steady-state and inducible negative regulation. Further kinetics and substrate avidity studies are necessary to explain the similar molecular targets between these two molecules.
Studies utilizing independently generated Cyld −/− mice have yielded highly insightful findings, albeit somewhat conflicting. In one study, the Cyld −/− animals demonstrated significant defects in NF-B and JNK signaling in macrophages following TLR and CD40 stimulation. 151 However, this effect appeared to be stimuli specific, as TNF stimulation did not appear to be impacted by CYLD deficiency. 151 Importantly, this study observed normal B and T-cell development and function. 151 While there are several differences in the proposed mechanistic actions of CYLD, these findings are in general agreement with other groups using these and other independently generated Cyld −/− animals. 152, 153 However, at least one additional group has not observed these phenotypes using another independently generated Clyd −/− mouse line. 154 These animals did not recapitulate the defects in NF-B, JNK, ERK, or p38 signaling. 154 Rather, these animals showed significant attenuation of TCR signaling in the absence of CYLD. 154 
Cezanne
Cellular zinc finger anti-NF-B (Cezanne) is a 100 kDa protein with sequence similarity to A20. 155, 156 Because of this, its potential role in NF-B attenuation has been extensively studied. Like A20, Cezanne is a negative regulator of NF-B signaling, which has been shown using overexpression studies in HEK-293 cells. 156 In this model, overexpression of Cezanne reduced NF-B activity after stimulation with TNF. 156 Cezanne was further found to be inducible in HEK-293 cells following stimulation with TNF, suggesting the presence of a feedback loop consistent with many of the negative regulators of NF-B signaling. 157 Mechanistically, Cezanne was shown to interact with TRAF6 by coimmunoprecipation following overexpression. 156 Further studies revealed that Cezanne cleaves monomers from linear or branched poly-Ub chains and thus acts as a DUB. 155 In endothelial cells pretreated with specific Cezanne siRNAs, TRAF6 coprecipitates with Lys-63 poly-Ub chains, whereas this same result is not seen in control cells without the siRNAs. 158 Together, the data from these studies indicate that Cezanne can inhibit canonical NF-B signaling through the de-ubiquitination of TRAF6 both in vitro and in vivo (Fig. 5 ).
It should also be mentioned that Cezanne has also been reported to play a role in the negative regulation of the noncanonical NF-B pathway. 159 Hu et al. (2013) showed that cells that were deficient in Cezanne had a significant increase in nuclear levels of p52, compared to wild type, after stimulating the noncanonical NF-B activating receptors, LT R, CD40, and BAFFR. 159 Furthermore, compared to wild type, cells that lacked Cezanne show a much higher level of TRAF3 Lys-48 ubiquitination, degradation, and NIK accumulation after treatment with noncanonical NF-B agonists. 159 Therefore, it can be said that Cezanne is an important negative regulator of inflammation via its ability to attenuate both the canonical and noncanonical NF-B pathways.
CROSSTALK BETWEEN THE CANONICAL AND NONCANONICAL NF-KB PATHWAYS
The . 162 Mechanistically, it seems that an accumulation of NIK via the lack of TRAF3, may lead to an amplification of IKK activity and a subsequent increase in both canonical and noncanonical NF-kB activity. 162 Indirectly, both canonical and noncanonical NF-B signaling pathways can communicate via many of the negative regulators discussed in this review. For example, the I B family of molecules and the DUB cezanne clearly play important roles in negatively regulating both pathways. However, other molecules have also been shown to overlap as well, although sometimes having opposite pathway-specific affects.
A20 is an excellent example of this dichotomy. As discussed above, A20 is a potent regulator of canonical NF-B signaling. However, in cells stimulated with noncanonical pathway agonists, processing of p100 to p52 is significantly reduced in cells treated with siRNAs for A20. 163 This was further confirmed using A20 −/-MEFs stimulated with the same agonists, resulting in reduced NIK accumulation and p100 processing. 163 Interestingly, stimulation with CD40L induced NIK accumulation regardless of whether A20 was present or absent, suggesting an A20-independent mechanism for the noncanonical pathway under these conditions. 163 RIP-1 is another mediator of NF-B signaling that has opposing effects on the two pathways. As mentioned earlier, RIP1 activates the canonical NF-B pathway downstream of the TNF receptor.
However, it also negatively regulates the noncanonical pathway via inhibition of TRAF2 degradation. TNF treatment in MEFs lacking RIP1 revealed TRAF2 degradation, which coincided with an increase in p100 processing. 164 Because TRAF2 plays a role in the recruitment of cIAP1/2 to the TRAF-cIAP1/2 complex, which is responsible for targeting NIK for degradation, it stands to reason that its degradation would lead to accumulation of NIK. Indeed, NIK was shown to be stabilized in MEFs lacking RIP-1 and treated with TNF compared to WT cells. 164 While TNF stimulation is widely accepted to activate the canonical pathway via recruitment of RIP-1 to TNFR1, this same series of events seems to inhibit TRAF2 degradation. Thus, NIK is unable to become stabilized, resulting in inhibition of the noncanonical pathway.
CONCLUSIONS
The mechanisms associated with the attenuation and resolution of inflammation are still being defined. This stands in contrast to the extensive data pertaining to immune system activation and signaling.
One can certainly argue that having an organized system of molecular checks and balances to prevent hyperactive immune system signaling is vital due to the collateral damage that uncontrolled inflammation can Ringel-Scaia was supported through the American Association of
Immunologists Careers in Immunology Fellowship Program. We apologize to any colleagues whose work was not included due to length constraints.
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